Scientific publications

Related to drug candidate CS585:

CS585 is a novel orally available prostacyclin receptor agonist with sustained in vivo inhibition of platelets and thrombosis formation in mouse without increased risk of bleeding

Sylviane Lambert, Pooja Yalavarthi, Livia Stanger, Adriana Yamaguchi, Michael Holinstat, Niklas Bergh, Björn Dahlöf. ACC.23/WCC Congress 2023.

Related to epigenetic modulation and HDACi:

Histone deacetylase inhibitors for cardiovascular conditions and healthy longevity.

João Pedro Ferreira, Bertram Pitt, Faiez Zannad.
The Lancet Healthy Longevity, Volume 2, Issue 6, 2021, pages e371-e379, ISSN 2666-7568, doi.org/10.1016/S2666-7568(21)00061-1.

Related to CS1's Phase I study:

A First in Class Treatment for Thrombosis Prevention. A Phase I study with CS1, a New Controlled Release Formulation of Sodium Valproate

Niklas Bergh, Jan-Peter Idström, Henri Hansson, Jonas Faijerson-Säljö, Björn Dahlöf.
Journal of Cardiology and Vascular Medicine 2019 Volume 5: 1-12.

Related to CS1's Phase II study:

Investigation of efficacy, safety and optimal dose of CS1 in subjects with pulmonary arterial hypertension: a prospective, randomized, multicenter, parallel-group phase II study

Raymond Benza, Niklas Bergh, Philip Adamson, Björn Dahlöf. PVRI congress 2022.

Publications related to drug candidate CS585:

CS585 is a first-in-class compound targeting the IP receptor for prevention of thrombosis without increased risk of bleeding

Sylviane Lambert, Reheman Adili, Pooja Yalavarthi, Nicole Rhoads, Björn Dahlöf, Andrew White, Niklas Bergh, Michael Holinstat. HemaSphere, 2022; 6:S3.